Tazemetostat

Drug Profile

Tazemetostat

Alternative Names: E-7438; EPZ-6438

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Epizyme
  • Developer Eisai Co Ltd; Epizyme; Genentech; National Cancer Institute (USA)
  • Class Amines; Antineoplastics; Biphenyl compounds; Dihydropyridines; Morpholines; Small molecules
  • Mechanism of Action EZH2 enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Rhabdoid tumour
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Histiocytosis; Mesothelioma; Non-Hodgkin's lymphoma; Rhabdoid tumour; Solid tumours; Synovial sarcoma
  • Phase I B cell lymphoma; Mantle-cell lymphoma

Most Recent Events

  • 04 Aug 2017 Epizyme and Genentech plans a phase Ib/II MORPHEUS trial for Non-small cell lung cancer (Combination therapy, Metastatic disease) by the end of 2017
  • 04 Aug 2017 Epizyme completes enrolment in its phase II trials in Mesothelioma (Second-line therapy or greater) in United Kingdom, France and USA (PO)
  • 24 Jul 2017 Phase-II clinical trials in CNS cancer (In children, In infants, Late-stage disease, Second-line therapy or greater, In adults) in USA (PO) (NCT03213665; 9220028)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top